A phase I/IIa study in 24 patients with advanced HPV-associated cancers, including six HNSCC, investigated an LP vaccine directed against the p16INK4a protein and found that 64% of patients had SD and 36% had PD (median follow-up: 5.6 months). This evidence concerns the gene CDKN2A and cancer.